En undersøgelse til at sammenligne effektiviteten, sikkerheden og tolerabiliteten af FF/UMEC/VI med FF/VI hos 12-17-årige med astma
En fase 3, 24-ugers, randomiseret, dobbeltblind, parallel-gruppe Bayesiansk dynamisk låneundersøgelse, der sammenligner effektiviteten, sikkerheden, tolerabiliteten og farmakokinetikken af FF/UMEC/VI med FF/VI hos 12-17-årige deltagere med Utilstrækkeligt kontrolleret astma på stabil vedligeholdelsesterapi med ICS/LABA
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Buenos Aires, Argentina, C1425BEN
- GSK Investigational Site
-
Buenos Aires, Argentina, C1202
- GSK Investigational Site
-
Buenos Aires, Argentina, 1888
- GSK Investigational Site
-
Buenos Aires, Argentina, 1122
- GSK Investigational Site
-
Buenos Aires, Argentina, C1023AAB
- GSK Investigational Site
-
Córdoba, Argentina, X5000DCE
- GSK Investigational Site
-
Córdoba, Argentina, X5014AKM
- GSK Investigational Site
-
Lanus, Argentina, B1824KAJ
- GSK Investigational Site
-
Lobos, Argentina, 7240
- GSK Investigational Site
-
Lujan de Cuyo, Argentina, 5509
- GSK Investigational Site
-
Mar del Plata, Argentina, 7600
- GSK Investigational Site
-
Rosario, Argentina, 2000
- GSK Investigational Site
-
Rosario Provincia de Santa FE, Argentina, 2000
- GSK Investigational Site
-
San Miguel de Tucumán, Argentina, T4000IHE
- GSK Investigational Site
-
Santa Fe, Argentina, 3000
- GSK Investigational Site
-
-
-
-
Queensland
-
South Brisbane, Queensland, Australien, 4101
- GSK Investigational Site
-
-
South Australia
-
North Adelaide, South Australia, Australien, 5006
- GSK Investigational Site
-
-
Western Australia
-
Joondalup WA, Western Australia, Australien, 6027
- GSK Investigational Site
-
-
-
-
-
Lo Barnechea, Chile, 7691236
- GSK Investigational Site
-
Santiago, Chile, 7630000
- GSK Investigational Site
-
Santiago, Chile, 8320000
- GSK Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35244
- GSK Investigational Site
-
Mobile, Alabama, Forenede Stater, 36608
- GSK Investigational Site
-
-
Arizona
-
Paradise Valley, Arizona, Forenede Stater, 85253
- GSK Investigational Site
-
-
California
-
Bakersfield, California, Forenede Stater, 93301-4205
- GSK Investigational Site
-
Huntington Beach, California, Forenede Stater, 92647
- GSK Investigational Site
-
Mission Viejo, California, Forenede Stater, 92691
- GSK Investigational Site
-
Rolling Hills Estates, California, Forenede Stater, 90274
- GSK Investigational Site
-
-
Colorado
-
Colorado Springs, Colorado, Forenede Stater, 80909
- GSK Investigational Site
-
-
Florida
-
Aventura, Florida, Forenede Stater, 33180
- GSK Investigational Site
-
Miami, Florida, Forenede Stater, 33173
- GSK Investigational Site
-
Miami, Florida, Forenede Stater, 33165
- GSK Investigational Site
-
Miami, Florida, Forenede Stater, 33174
- GSK Investigational Site
-
-
Georgia
-
Savannah, Georgia, Forenede Stater, 31406
- GSK Investigational Site
-
-
Illinois
-
Normal, Illinois, Forenede Stater, 61761
- GSK Investigational Site
-
-
Kentucky
-
Owensboro, Kentucky, Forenede Stater, 42301
- GSK Investigational Site
-
-
Missouri
-
Columbia, Missouri, Forenede Stater, 65203
- GSK Investigational Site
-
-
Montana
-
Missoula, Montana, Forenede Stater, 59808
- GSK Investigational Site
-
-
New York
-
The Bronx, New York, Forenede Stater, 10461-1119
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45229
- GSK Investigational Site
-
Cleveland, Ohio, Forenede Stater, 44106
- GSK Investigational Site
-
Dayton, Ohio, Forenede Stater, 45404
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73120-9350
- GSK Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29420
- GSK Investigational Site
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75225-6301
- GSK Investigational Site
-
Kerrville, Texas, Forenede Stater, 78028
- GSK Investigational Site
-
Plano, Texas, Forenede Stater, 75034
- GSK Investigational Site
-
Waco, Texas, Forenede Stater, 76712
- GSK Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- GSK Investigational Site
-
-
-
-
-
Ashkelon, Israel, 7830604
- GSK Investigational Site
-
Haifa, Israel, 3436212
- GSK Investigational Site
-
Haifa, Israel, 3109600
- GSK Investigational Site
-
Petah Tikva, Israel, 49202
- GSK Investigational Site
-
-
-
-
-
Guadalajara, Mexico, 44100
- GSK Investigational Site
-
Monterrey, Mexico, 64460
- GSK Investigational Site
-
San Juan del Río, Mexico, 76800
- GSK Investigational Site
-
-
-
-
Upper Hutt
-
Ebdentown, Upper Hutt, New Zealand, 5018
- GSK Investigational Site
-
-
-
-
-
Cheongju Chungcheongbuk-do, Sydkorea, 28644
- GSK Investigational Site
-
Gwangju, Sydkorea, 501-757
- GSK Investigational Site
-
Seoul, Sydkorea, 05505
- GSK Investigational Site
-
Seoul, Sydkorea, 03722
- GSK Investigational Site
-
Seoul, Sydkorea, 1757
- GSK Investigational Site
-
Seoul, Sydkorea, 2447
- GSK Investigational Site
-
-
-
-
-
Adana, Tyrkiet (Türkiye), 1173
- GSK Investigational Site
-
Antalya, Tyrkiet (Türkiye), 07070
- GSK Investigational Site
-
Istanbul, Tyrkiet (Türkiye), 34010
- GSK Investigational Site
-
Istanbul, Tyrkiet (Türkiye), 34899
- GSK Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participant must be 12 to 17 years of age (inclusive), at the time of signing the informed consent/assent.
- Participants who have a diagnosis of asthma as defined by the National Institutes of Health [NIH, 2020] at least 1 year prior to Visit 0.
- Participants who have required daily Inhaled corticosteroids (ICS)/ Long-Acting Beta2-Agonist (LABA) treatment for at least 12 weeks prior to Visit 0 with no changes to maintenance asthma medications during the 6 weeks immediately prior to Visit 0 (including no changes to a stable total ICS dose of >250 to <=500 microgram (mcg)/day fluticasone propionate, or equivalent).
- In the 1 year prior to Visit 1: A documented healthcare contact for acute asthma symptoms; OR A documented temporary change in asthma therapy for acute asthma symptoms, according to a prespecified asthma action plan (or equivalent).
- Participants with inadequately controlled asthma (ACQ-6 score ≥1.5) at Visit 1, despite ICS/LABA maintenance therapy.
- A best pre-bronchodilator FEV1 >40% to <=90% of the predicted normal value and a ≥12% increase in FEV1 with albuterol/salbutamol at Visit 1. Predicted values will be based on the European Respiratory Society (ERS) Global Lung Function Initiative.
Exclusion Criteria:
- Chest X-ray documented pneumonia in the 6 weeks prior to Visit 1.
- Any asthma exacerbation requiring a change in maintenance asthma therapy and/or the use of systemic corticosteroids for at least 3 days in the 6 weeks prior to Visit 1. (Participants requiring a temporary change in asthma therapy (e.g., oral corticosteroids or increased dose of ICS) to treat an exacerbation in the 6 weeks prior to Visit 1 are not explicitly excluded at Visit 1 provided that, at the Investigator's discretion, the participant's condition is stable after they have resumed their pre-exacerbation maintenance asthma therapy (without modification), returned to their baseline asthma status and they are considered appropriate for enrollment into this study of up to 6 months duration)
- History of Life-threatening Asthma
- Participants with current evidence of active pulmonary diseases or abnormalities other than asthma (e.g., pneumonia, active tuberculosis, significant bronchiectasis, etc.).
- Current smokers and users of other inhaled products for recreation with or without nicotine (defined as participants who use cigarettes, e-cigarettes, other/vaping-related devices, cigars or pipe tobacco]) within 12 months prior to Visit 1.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Deltagere, der modtager FF/UMEC/VI
|
FF/UMEC/VI will be administered. FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler |
|
Aktiv komparator: Deltagere, der modtager FF/VI
|
FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler FF/VI will be administered. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in trough forced expiratory volume in 1 second (FEV1) (Liters) at Week 24
Tidsramme: Baseline (Week 0) and Week 24
|
FEV1 will be measured using spirometry. |
Baseline (Week 0) and Week 24
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in Asthma Control Questionnaire (7 items) (ACQ-7) (Scores on a scale)
Tidsramme: Baseline (Week 0) and Week 24
|
ACQ-7 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation)), a question on rescue use and an additional item relating to lung function which is calculated based on FEV1. A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma. |
Baseline (Week 0) and Week 24
|
|
Change from Baseline in Asthma Control Questionnaire (6 items) (ACQ-6) (Scores on a scale)
Tidsramme: Baseline (Week 0) and Week 24
|
ACQ-6 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation)) and a question on rescue bronchodilator use. A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma. |
Baseline (Week 0) and Week 24
|
|
Change from Baseline in Asthma Control Questionnaire (5 items) (ACQ-5) (Scores on a scale)
Tidsramme: Baseline (Week 0) and Week 24
|
ACQ-5 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma. |
Baseline (Week 0) and Week 24
|
|
Number of Participants with a clinically important change from baseline in ACQ-7 Score
Tidsramme: Week 24
|
ACQ-7 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation)), a question on rescue use and an additional item relating to lung function which is calculated based on FEV1. A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in score. |
Week 24
|
|
Number of Participants with a clinically important change from baseline in ACQ-6 Score
Tidsramme: Week 24
|
ACQ-6 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation)) and a question on rescue bronchodilator use. A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in score. |
Week 24
|
|
Number of Participants with a clinically important change from baseline in ACQ-5 Score
Tidsramme: Week 24
|
ACQ-5 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in score. |
Week 24
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: GSK Clinical Trials, GlaxoSmithKline
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 206867
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD-delingstidsramme
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD-delingsadgangskriterier
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .